# US 2025/0368998 A1 · Nucleotide analogues, and preparation and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0368998 A1
- Document ID: US20250368998A1
- Status: Published application
- Kind: A1
- Application number: 19/300,802
- Filed: 2025-08-15
- Published: 2025-12-04
- Earliest claimed: 2023-02-21
- Assignees: Hitgen Inc.
- Applicants: Hitgen Inc.
- Inventors: Jin LI; Shuai ZHANG; Huiyong MA; Guansai LIU; Yongjian HU; Chongfei BO; Huadong LUO
- Web page: https://patentgrep.com/patent/US20250368998A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07F 9/6512: having the nitrogen atoms in positions 1 and 3
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/333: Modified A
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/335: Modified T or U
- C12N 2310/336: Modified G
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12Y: ENZYMES
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

A lipophilic nucleotide analogue of the following formula: where Y is a hydroxyl protecting group, R1 is a C1-6 alkyl or a halogen-substituted C1-6 alkyl, R2 is a C1-6 alkyl or a halogen-substituted C1-6 alkyl, L is a lipophilic group; and Base is a nucleotide base. A preparation of the nucleotide analogue from is provided. A method for enhancing the in-vivo delivery of nucleic acid drugs with the nucleotide analogue is also provided.

## Claims

### Claim 1

A compound of formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof:
wherein Y is a hydroxyl protecting group;
R1 is a C1-6 alkyl or a halogen-substituted C1-6 alkyl;
R2 is a C1-6 alkyl or a halogen-substituted C1-6 alkyl;
L is a lipophilic group; and
Base is a nucleotide base.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is isopropyl;
R2 is isopropyl; and
L is a cholesteryl group or a C6-20 alkyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein L is selected from the group consisting of

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the Base is selected from the group consisting of

### Claim 5 (depends on 1)

The compound according to claim 1, wherein Y is selected from the group consisting of 4,4′-dimethoxytrityl, 4-methoxytrityl, trityl, trimethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, triethylsilyl, phenyldimethylsilyl, benzyloxycarbonyl and 2-bromobenzyloxycarbonyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein the compound is represented by:

### Claim 7

A method for synthesizing a nucleotide analogue, comprising:
(1) dissolving a compound A1 in dichloromethane followed by addition of Dess-Martin periodinane and NaHCO3 and reaction at room temperature for 5-16 h to obtain a compound A2;
(2) dissolving ethyl (triphenylphosphoranylidene) acetate in dichloromethane followed by addition of a dichloromethane solution of the compound A2 under stirring and reaction at room temperature for 5-16 h to obtain a compound A3;
(3) dissolving the compound A3 in dichloromethane followed by addition of diisobutyl aluminum hydride and reaction at −10° C.-5° C. for 1-3 h to obtain a compound A4;
(4) dissolving tetraisopropyl titanate in dichloromethane followed by addition of diethyl D-(−)-tartrate under stirring at −30° C.-5° C., addition of a dichloromethane solution of the compound A4 and tert-butyl hydroperoxide, and reaction for 10-24 h to obtain a compound A5;
(5) dissolving the compound A5 in pyridine followed by addition of a hydroxyl protecting group reagent and reaction at room temperature under stirring for 5-16 h to obtain a compound A6;
(6) dissolving the compound A6, a nucleotide base reagent and 1,8-diazabicyclo [5.4.0] undec-7-ene in a solvent in a microwave reaction tube followed by reaction under stirring at 90-120° C. for 5-12 h to obtain a compound A7; and
(7) dissolving the compound A7 in dichloromethane followed by addition of 4,5-dicyanoimidazole and 2-cyanoethyl N,N,N′,N′-tetraisopropyl-phosphordiamidite and reaction at 20-40° C. for 20 min-3 h to obtain a compound A8; as shown in the following synthesis route:

### Claim 8 (depends on 7)

The method according to claim 7, wherein in step (1), a molar equivalent ratio of the compound A1 to the Dess-Martin periodinane to NaHCO3 is 1:1.0-1.5:2-6;
in step (2), a molar equivalent ratio of the compound A2 to ethyl (triphenylphosphoranylidene) acetate is 1:1.0-1.5;
in step (3), a molar equivalent ratio of the compound A3 to diisobutyl aluminum hydride is 1:2.0-3.0;
in step (4), a molar equivalent ratio of the compound A4 to tetraisopropyl titanate to diethyl D-(−)-tartrate is 1:1.0-1.5:1.0-1.5;
in step (5), a molar equivalent ratio of the compound A5 to the hydroxyl protecting group reagent is 1:1.0-1.5;
in step (6), a molar equivalent ratio of the compound A6 to the nucleotide base reagent to 1,8-diazabicyclo [5.4.0] undec-7-ene is 1:1.0-2.0:1.0-2.0; and
in step (7), a molar equivalent ratio of the compound A7 to 4,5-dicyanoimidazole to 2-cyanoethyl N,N,N′,N′-tetraisopropyl-phosphordiamidite is 1:0.5-2.0:1.0-2.5.

### Claim 9 (depends on 7)

The method according to claim 7, wherein in step (1), a molar equivalent of the compound A1 is 1, a molar equivalent of the Dess-Martin periodinane is 1.0, 1.1, 1.2, 1.3, 1.4 or 1.5, and a molar equivalent of NaHCO3 is 2, 3, 4, 5 or 6;
in step (2), a molar equivalent of the compound A2 is 1, and a molar equivalent of ethyl (triphenylphosphoranylidene) acetate is 1.0, 1.1, 1.2, 1.3, 1.4 or 1.5;
in step (3), a molar equivalent of the compound A3 is 1, and a molar equivalent of diisobutyl aluminum hydride is 2.1, 2.2, 2.4, 2.6, 2.7, 2.8 or 3.0;
in step (4), a molar equivalent of the compound A4 is 1, a molar equivalent of tetraisopropyl titanate is 1.0, 1.1, 1.2, 1.3, 1.4 or 1.5, and a molar equivalent of diethyl D-(−)-tartrate is 1.0, 1.1, 1.2, 1.3, 1.4 or 1.5;
in step (5), a molar equivalent of the compound A5 is 1, and a molar equivalent of the hydroxyl protecting group reagent is 1.0, 1.1, 1.2, 1.3, 1.4 or 1.5;
in step (6), a molar equivalent of the compound A6 is 1, a molar equivalent of the nucleotide base reagent is 1.2, 1.3, 1.4, 1.5, 1.6, 1.7 or 1.8, and a molar equivalent of 1,8-diazabicyclo [5.4.0] undec-7-ene is 1.2, 1.3, 1.4, 1.5, 1.6, 1.7 or 1.8; and
in step (7), a molar equivalent of the compound A7 is 1, a molar equivalent of 4,5-dicyanoimidazole is 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0, and a molar equivalent of 2-cyanoethyl N,N,N′,N′-tetraisopropyl-phosphordiamidite is 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1 or 2.2.

### Claim 10 (depends on 7)

The method according to claim 7, wherein in step (5), the hydroxyl protecting group reagent is 4,4′-dimethoxytrityl chloride; and
in step (6), the nucleotide base reagent is uracil.

### Claim 11 (depends on 7)

The method according to claim 7, wherein in step (1), the reaction is performed for 5 h, 8 h, 10 h, 12 h, 14 h or 16 h;
in step (2), the reaction is performed for 5 h, 8 h, 10 h, 12 h, 14 h or 16 h;
in step (3), the reaction is performed at −10° C., −5° C., 0° C. or 5° C. for 1 h, 2 h or 3 h;
in step (4), the reaction is performed at −30° C., −25° C., −10° C., 0° C. or 5° C. for 10 h, 12 h, 16 h, 18 h, 20 h, 22 h or 24 h;
in step (5), the reaction is performed for 5 h, 8 h, 10 h, 12 h, 14 h or 16 h;
in step (6), the reaction is performed at 90° C., 100° C., 110° C. or 120° C. for 5 h, 8 h, 10 h, 12 h, 14 h or 16 h; and
in step (7), the reaction is performed at 20° C., 25° C., 30° C. or 35° C. for 20 min, 0.5 h, 1 h or 2 h.

### Claim 12

A small interfering RNA (siRNA), comprising:
a sense strand; and
an antisense strand;
wherein the sense strand and the antisense strand each comprise 15-45 nucleotides which are each independently modified or unmodified;
the sense strand and the antisense strand are partially complementary to form a double-stranded region; and
the sense strand comprises at least one nucleotide represented by Formula (V) in the 15-45 nucleotides:
the at least one nucleotide represented by Formula (V) is covalently linked to other parts of the siRNA at position;
wherein X is O or S;
L is a lipophilic group; and
Base is a nucleotide base.

### Claim 13 (depends on 12)

The siRNA according to claim 12, wherein the at least one nucleotide represented by Formula (V) is represented by Formula (Va):
wherein X is O or S;
L is the lipophilic group; and
the Base is the nucleotide base.

### Claim 14 (depends on 12)

The siRNA according to claim 12, wherein L is a cholesteryl group or a C6-20 alkyl.

### Claim 15 (depends on 14)

The siRNA according to claim 14, wherein L is selected from the group consisting of

### Claim 16 (depends on 12)

The siRNA according to claim 12, wherein the Base is selected from the group consisting of

### Claim 17 (depends on 12)

The siRNA according to claim 12, wherein the at least one nucleotide represented by Formula (V) is represented by:

### Claim 18 (depends on 12)

The siRNA according to claim 12, wherein a nucleotide at position 2, 3, 4, 5, 6, 7, 8, 9 or 10 from 5′-end of the sense strand is represented by the Formula (V).

### Claim 19 (depends on 12)

The siRNA according to claim 12, wherein the antisense strand has a length of 19-27 nucleotides, and the sense strand has a length of 19-25 nucleotides.

### Claim 20 (depends on 12)

The siRNA according to claim 12, wherein the siRNA comprises at least one modified nucleotide or nucleotide analogue.

### Claim 21 (depends on 20)

The siRNA according to claim 20, wherein the at least one modified nucleotide or nucleotide analogue is independently selected from the group consisting of 2′-O-methyl nucleotide, 2′-fluoro nucleotide, 2′-deoxy nucleotide, 2′,3′-seco nucleoside analogue, 2′-fluoroarabino nucleotide, 2′-O-methoxyethyl nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, 3′-O-methyl nucleotide, 2′-allyl-modified nucleotide, a phosphorothioate group-containing nucleotide, a methyl phosphonate group-containing nucleotide, a 5′-phosphate group-containing nucleotide, a 5′-phosphate mimic-containing nucleotide, a diol-modified nucleotide, an abasic nucleotide, a morpholino nucleotide, a locked nucleic acid, an unlocked nucleic acid and a glycerol nucleotide.

### Claim 22 (depends on 20)

The siRNA according to claim 20, wherein 5′-end and 3′-end of the sense strand each independently comprises one or two phosphorothioate groups; and
5′-end and 3′-end of the antisense strand each independently comprises one or two phosphorothioate groups.

### Claim 23 (depends on 12)

A pharmaceutical composition, comprising:
the siRNA according to claim 12; and
a pharmaceutically acceptable carrier.

### Claim 24 (depends on 12)

A method for enhancing in-vivo delivery of a nucleic acid drug in a subject in need thereof, comprising:
administering the siRNA according to claim 12 to the subject.
